Name/Company | Approval Dates and Comments |
Alitretinoin Toctino® Basilea Pharmaceuticals | The French regulatory authority approved this retinoid in October 2008 for the treatment of severe chronic refractory hand eczema unresponsive to potent topical corticosteroids in adults. Also approved by the Danish Medicines Agency in September 2008. Marketing applications for this product are also under review in Canada and Switzerland. |
Denileukin Diftitox Ontak™ Esai Corporation | The US FDA approved this solution for intravenous injection in October 2008 for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma whose malignant cells express the CD25 component of the IL-2 receptor (CD25+). |
Bimatoprost Ophthalmic 0.03% Solution LATISSE® Allergan | The US FDA approved this ophthalmic solution in Dec 2008 as a novel treatment for hypotrichosis of the upper eyelashes. |
Maraviroc SELZENTRY® Pfizer | The US FDA approved this CCR5 antagonist in November 2008 for use in treatment-experienced adults with CCR5-tropic HIV-1 in combination with other antiretroviral agents. |
Clindamycin Phosphate 1.2% + Benzoyl Peroxide 2.5% Acanya® Gel Arcutis Pharmaceuticals | The US FDA approved this fixed combination antibiotic and benzoyl peroxide formulation in November 2008 for the once daily treatment of both non-inflammatory and inflammatory acne lesions in patients 12 years of age and older. |
Etanercept Enbrel® Wyeth | The European Medicines Agency (EMEA) approved this product in January 2009 for the treatment of chronic severe plaque psoriasis in children aged 8 years and above. |